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SafetyThis 24-week, open-label, Phase Ib, parallel-arm, multiple-dose trial assessed the pharmacokinetics, safety
and tolerability of a once-monthly injection of aripiprazole (aripiprazole once-monthly) in 41 subjects
with schizophrenia. The objective was to determine if aripiprazole plasma concentrations (at doses of 200,
300 and 400 mg) were within the therapeutic range observed for the oral tablet (10–30 mg). Completion
rates were 36.4% (n = 4/11), 50.0% (n = 8/16) and 71.4% (n = 10/14) for the 200 mg, 300 mg and
400 mg groups, respectively. Patients were stabilized on oral aripiprazole (10 mg/day) before the ﬁrst injection
and received oral aripiprazole (10 mg/day) concomitantly with the ﬁrst dose of aripiprazole once-monthly for
14 days. Administration of aripiprazole once-monthly at doses of 300 and 400 mg provided sustained mean
aripiprazole plasma concentrations comparable with the concentration range observed following multiple con-
secutive daily doses of oral aripiprazole. In contrast, plasma concentrations following administration of
aripiprazole once-monthly at a dose of 200 mg were below the therapeutic range and pharmacokinetic param-
eters were not proportional to the administered dose compared with the 300 mg and 400 mg doses. Treatment
with aripiprazole once-monthly, at any dose, did not result in any clinicallymeaningful changes from baseline in
extrapyramidal symptom scales, clinical laboratory tests, vital signs, or electrocardiogram parameters. The most
common treatment-emergent adverse events were vomiting (13.3%, 300 mg; 14.3%, 400 mg), injection site pain
(28.6%, 400 mg), upper respiratory tract infection (10%, 200 mg; 6.7% 300 mg; 14.3%, 400 mg) and tremor
(6.7%, 300 mg; 21.4%, 400 mg). In conclusion, aripiprazole once-monthly at doses of 300 and 400 mg is a
viable formulation for treatment of adults with schizophrenia.
© 2013 The Authors. Published by Elsevier B.V.Open access under CC BY-NC-ND license.  1. Introduction
The long-term course of schizophrenia is frequently characterized
by reduced social and occupational functioning, loss of independente American Psychiatric Associ-
evelopment and Commerciali-
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.V.Open access under CC BY-NC-ND licliving, impaired quality of life, substance abuse and an increased risk
of suicidal and violent behavior (Wiersma et al., 2000). Maintenance
treatment with antipsychotics is, therefore, a key feature of long-term
management. However, partial or non-adherence to medication is
an important barrier in achieving long-term success (Velligan et al.,
2009). Rates of non-adherence to antipsychotic medication are high
and are associatedwith a signiﬁcantly increased risk of relapse and hos-
pitalization (Gilmer et al., 2004; Kane, 2006; Valenstein et al., 2006;
Nasrallah, 2007).
Long-acting injectable (LAI) antipsychotics relieve patients from the
daily need to takemedication and subsequently have thepotential to im-
prove adherence (Kane, 2006). Furthermore, failure to attend an injec-
tion visit serves as a signal for treatment non-adherence (Lindenmayer,
2010). Three new-generation antipsychotics with long-acting formula-
tions are approved in the US and Europe for treatment of schizophrenia:
risperidone LAI (Fleischhacker et al., 2003; Kane et al., 2003), olanzapine
LAI (Lauriello et al., 2008; Kane et al., 2010) and paliperidone palmitateense.  
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where (Fleischhacker, 2009; Rauch, 2013).
More recently, aripiprazole once-monthly, a long-acting injectable
formulation of oral aripiprazole has been approved in the US for the
treatment of schizophrenia. The established efﬁcacy and safety proﬁle
of oral aripiprazole for treatment of schizophrenia and bipolar disorder
(McIntyre et al., 2007; Stip and Tourjman, 2010), alongside preliminary
pharmacokinetic (PK) data from subjects receiving multiple daily doses
of oral aripiprazole, made it a candidate for development into a long-
acting formulation. Two, 14-day studies investigating pharmacokinetics,
tolerability and safety of oral aripiprazole in healthy volunteers showed
that multiple once-daily doses of oral aripiprazole had linear pharmaco-
kinetics (ﬁxed dose: 5, 10, 15, and 20 mg; ﬂexible dose: 10–30 mg/day)
(Mallikaarjun et al., 2004).Mean elimination half-lives for the ﬁxed-dose
and ﬂexible-dose trial were 47–68 h and 59 h, respectively. Subjects
generally reached steady state by Day 14. The Cmax at Day 14 for
aripiprazole doses 10 to 30 mg/day was 163 to 452 ng/mL
(Mallikaarjun et al., 2004).
The current study evaluated the pharmacokinetics, tolerability
and safety of three different doses (200, 300, and 400 mg) of
aripiprazole once-monthly (administered as 5 monthly injections
of aripiprazole once-monthly over a 4-month period) for treatment
of adults with schizophrenia.
2. Methods
2.1. Study design
This 24-week, open-label, parallel-arm study assessed the phar-
macokinetics, safety, and tolerability of aripiprazole once-monthlyFig. 1. Study design. aDuring screening, subjects taking antipsychotics other than aripiprazolew
stability for 14 days; subjects already receiving oral aripiprazole 10 mg/day had to demo
downtitrated to 10 mg/day over a 14-day period in step sizes according to the investigator's
to 32 subjects were initially randomized to aripiprazole once-monthly-400 and aripiprazole o
once-monthly-200. All subjects received oral aripiprazole 10 mg for the ﬁrst 14 days followin
1 (the day of the ﬁrst aripiprazole once-monthly injection); subsequent clinic visits occurred
visit occurred between Days 6 and 8). cSubjects were permitted to resume oral aripiprazole o
(after the 4-week post-injection PK sample was obtained). However, subjects were encouraged t
chotics. PK = pharmacokinetic.in adults with schizophrenia. The study consisted of two phases:
a screening phase (up to 28 days), which included stabilization on
oral aripiprazole; and a randomization/treatment assignment phase
(24 weeks), in which patients received one of three different dose levels
of aripiprazole once-monthly (200 mg, 300 mg or 400 mg [referred
to as aripiprazole once-monthly-200, aripiprazole once-monthly-
300 and aripiprazole once-monthly-400, respectively]) as ﬁve injec-
tions over a 4-month period (Fig. 1).2.2. Dosing rationale
Aripiprazole plasma concentration–time proﬁles were simulated
based on PK parameters for a single-dose of aripiprazole once-
monthly and from previous oral steady-state studies (BMS data on
ﬁle). Based on these simulations, the lower 95% conﬁdence interval
of the minimum steady-state plasma drug concentrations during a
dosing interval (Css,min) for aripiprazole once-monthly-300 and
aripiprazole once-monthly-400 was expected to be above (or very
close to) the Css,min of daily dosing with 10 mg oral aripiprazole. An
aripiprazole once-monthly dose of 200 mg was also chosen in the
event of tolerability issues at higher doses and to provide further in-
sight into dose plasma level continuity.
Simulation modeling also indicated that the maintenance of
therapeutic concentrations observed with oral aripiprazole
(10–30 mg) was best achieved by supplementing the initial
aripiprazole once-monthly injection with oral aripiprazole
(10 mg/day) for the ﬁrst 14 days while aripiprazole concentrations
derived from the once-monthly injection reached therapeutic
levels.ere switched to oral aripiprazole 10 mg/day over a 14-day period and had to demonstrate
nstrate stability for 14 days; subjects on oral aripiprazole at doses N10 mg/day were
discretion followed by an additional 14 days at 10 mg/day to demonstrate stability. bUp
nce-monthly-300. A further 10 to 12 subjects were then assigned to receive aripiprazole
g the initial injection of aripiprazole once-monthly. The Week 1 visit was deﬁned as Day
at the beginning of the study week within a visit window of ±1 day (e.g. the Week 2
r their prestudy antipsychotic medication at the investigator's discretion after Week 20
o complete the entire study, including the PK sample at Week 25 before resuming antipsy-
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Eligible subjects were aged 18–64 years with a diagnosis of
schizophrenia according to the Diagnostic and Statistical Manual of
Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria
and with a body mass index of 18–35 kg/m2. Subjects needed to
have shown a previous response to antipsychotic medications other
than clozapine. Patients with any evidence of organ dysfunction or
with a medically signiﬁcant abnormal laboratory test, physical examina-
tion or electrocardiogram were excluded. Subjects with a DSM-IV-TR
diagnosis of schizoaffective or bipolar disorder were also excluded.
Eligible subjects had to be stable on their current antipsychotic
medication for at least 28 days or needed to be receiving oral
aripiprazole at ≥10 mg/day prior to enrolment. To facilitate the tran-
sition from oral to injectable antipsychotic, all subjects were stabi-
lized for ≥14 days on open-label oral aripiprazole (10 mg/day)
during screening (Day −28 to Day −1). This entailed one of the
following: subjects receiving oral aripiprazole 10 mg/day at enrolment
needed to be stable for 14 days prior to entering the randomization/
treatment assignment phase; subjects on oral antipsychotics other
than aripiprazole were switched to oral aripiprazole (10 mg/day over
a 14-day period) and needed to be stable at that dose for ≥14 days
prior to entering the randomization/treatment assignment phase; sub-
jects on oral aripiprazole at doses N10 mg/day were downtitrated to
10 mg/day over a 14-day period in step sizes based on the investigator's
discretion, followed by an additional 14 days at 10 mg/day to demon-
strate stability prior to randomization/treatment assignment.
Following the screening phase, eligible subjects were randomized
and assigned to aripiprazole once-monthly for a total of ﬁve injections
(administered on Day 1, and at the beginning of Weeks 5, 9, 13 and
17) (Fig. 1). Subjects received oral aripiprazole 10 mg for the ﬁrst
14 days following the initial injection of aripiprazole once-monthly.
AfterWeek 20, subjectswere permitted to resume their pre-studymed-
ication or to initiate treatment with another antipsychotic medication,
including oral aripiprazole, at the investigator's discretion. However,
subjects were encouraged to complete the entire study, including the
ﬁnal PK sample at Week 25 before resuming antipsychotics.
During the randomization/treatment assignment phase, weekly
outpatient visits were made through Week 21, including an addition-
al mid-week visit at Week 18.5 and at Weeks 23, 24 and 25. Week 24
was the protocol-deﬁned end-of-treatment visit. The Week 1 visit
was deﬁned as Day 1 (the day of the ﬁrst aripiprazole once-monthly
injection); subsequent clinic visits occurred at the beginning of the
study week within a visit window of ±1 day (e.g. the Week 2 visit
occurred between Days 6 and 8).
2.4. Concomitant medications
Mood stabilizing medications, antidepressants, and other psycho-
tropic agents were prohibited during the study and washed out
≥14 days prior to administration of aripiprazole once-monthly. In-
hibitors and inducers of CYP3A4 and inhibitors of CYP2D6 were also
not permitted. Benzodiazepines (lorazepam or lorazepam equivalent)
or anticholinergics were permitted during the screening period for
symptomatic relief, as clinically indicated. During the course of the
study, benzodiazepine or anticholinergics could be administered for
clinical indications other than prophylactic use, if deemed absolutely
necessary by the treating physician [although not within 4 and 12 h,
respectively, of extrapyramidal symptom (EPS) rating scale assessments].
2.5. Pharmacokinetic assessments
During aripiprazole once-monthly treatment, blood samples for
measurement of aripiprazole and dehydro-aripiprazole plasma con-
centrations were collected pre-dose [i.e. on Day 1 (Week 1), and
Weeks 5, 9, 13 and 17] as well as at Weeks 2, 3, 4, 6, 7, 8, 10, 11, 12,14, 15 and 16. After the ﬁnal dose (Week 17), samples were collected
at 1, 2, 3, 4, 6, 8, 12 and 24 h, then at 2, 3, 4 and 5 days, and at 1 week
(Week 18), 1.5 weeks (Week 18.5), 2 weeks (Week 19), 3 weeks
(Week 20), 4 weeks (Week 21), 6 weeks (Week 23) and 8 weeks
(Week 25). Subjects resuming oral aripiprazole or other antipsychotic
medication after Week 20 were excluded from PK analyses at Weeks
23 and 25.
2.6. Adverse events
Adverse events (AEs) and safety assessments were reported for all
subjects who received at least one injection of aripiprazole once-
monthly. Eventswere reported separately for the entire treatment period
(beginning with the ﬁrst aripiprazole once-monthly injection through to
the last visit) and for the co-administration period (co-administration AEs
were deﬁned as all AEs with onset between the ﬁrst and secondmonthly
aripiprazole once-monthly injection, even though the last dose of co-
administered oral aripiprazole was to occur on Day 14). For subjects
discontinuing prior to the second aripiprazole once-monthly injection,
all AEswere considered tohaveoccurred in the co-administration interval
up to the point of last contact.
2.7. Safety assessments
Extrapyramidal symptoms were monitored using the Simpson–
Angus scale (SAS) (Simpson and Angus, 1970), the Abnormal Invol-
untary Movement Scale (AIMS) (Guy, 1976a), and the Barnes
Akathisia Rating Scale (BARS) (Barnes, 1989). Subjects were assessed
at baseline, then every other week through Week 19 and at Weeks 20
and 24. Investigator assessment of local pain, tolerability and inﬂam-
mation at the injection site was evaluated by examining the AE proﬁle
pertaining to injection-site reactions.
Psychotic symptoms were evaluated using data from the Positive
and Negative Syndrome Scale (PANSS) (Kay et al., 1987) and Clinical
Global Impressions — Severity (CGI-S) scale (Guy, 1976b). The
PANSS was performed at baseline and monthly during the treatment
period and at Week 24. The CGI-S was completed at each weekly visit
through Week 20 and at Week 24.
2.8. Pharmacokinetic analysis
PK concentration–time proﬁles were performed on subjects who
received ≥3 doses of aripiprazole once-monthly and had PK samples
collected through ≥4 weeks following their last dose. PK parameters
were calculated based on data following the ﬁfth injection of
aripiprazole once-monthly. Primary PK parameters included the maxi-
mum andminimum steady-state plasma concentrations of aripiprazole
during the dosing interval (Css,max, Css,min) and the area under the
concentration–time curve during a dosing interval at steady-state
(AUCτ). Secondary PK parameters for aripiprazole included the time
to maximum (peak) plasma concentration (tmax), the average plasma
steady-state drug concentration during a dosing interval (Css,avg), the
apparent terminal-phase disposition rate constant (ﬁrst-order) (λz),
and the terminal-phase elimination half-life (t1/2,z).
2.9. Statistical analysis
Primary and secondary PK parameters and safety data were sum-
marized using descriptive statistics. Mean changes from baseline
were recorded at each visit for the PANSS total score and CGI-S
score, and analyzed using an analysis of covariance.
3. Results
The disposition of all 41 subjects who entered the randomization/
treatment assignment phase is summarized in Table 1. Completion
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aripiprazole once-monthly-200, -300 and -400, respectively. The
most common reasons for discontinuation were withdrawal of con-
sent for aripiprazole once-monthly-200 (n = 5), AEs for aripiprazole
once-monthly-300 (n = 4), and ‘met withdrawal criteria’ for
aripiprazole once-monthly-400 (n = 3) (Table 1). Baseline demo-
graphic characteristics and psychiatric history are summarized in
Table 2.
3.1. Concomitant medications
The most commonly used concomitant medications during treat-
ment with aripiprazole once-monthly are shown in Table 3. A total
of seven patients received concomitant medication with either risper-
idone or quetiapine (Table 3). In the majority of cases (5/7), these an-
tipsychotics were given for treatment of psychosis/schizophrenia
≥3 weeks after the last dose of aripiprazole once-monthly was ad-
ministered (i.e. following Week 20). In one of the other two cases, a
patient was switched from oral aripiprazole to oral risperidone fol-
lowing the initial dose of aripiprazole once-monthly but this patient
subsequently discontinued the study due to an AE of worsening of
schizophrenia. The ﬁnal patient received risperidone for a period of
approximately 4 weeks as part of a treatment plan for schizophrenia
following an error with the fourth injection, whereby an unknown dose
of aripiprazole once-monthly was administered instead of aripiprazole
once-monthly-300.
3.2. Pharmacokinetics
Mean plasma concentrations of aripiprazole prior to the third, fourth,
andﬁfth injections of aripiprazole once-monthlywere: aripiprazole once-
monthly-200: 60.3, 71.1, and 68.9 ng/mL; aripiprazole once-monthly-
300: 128, 185, and 175 ng/mL; and aripiprazole once-monthly-400:
152, 179, and 190 ng/mL (Fig. 2a). Aripiprazole plasma concentrations
were quantiﬁable in all subjectswith evaluable data at 2months follow-
ing the last injection and were in the range 37.9–157 ng/mL and
32.1–188 ng/mL for subjects receiving aripiprazole once-monthly-300
(n = 3) and aripiprazole once-monthly-400 (n = 6), respectively.Table 1
Disposition of all enrolled subjects.
Subjects Aripiprazole
once-monthly-200
n (%)
Aripiprazole
once-monthly-300
n (%)
Aripiprazole
once-monthly-400
n (%)
Enrolled 11 (100) 16 (100) 14 (100)
Completeda 4 (36.4) 8 (50.0) 10 (71.4)
Withdrawn 7 (63.6) 8 (50.0) 4 (28.6)
Adverse event 1 (9.1) 4 (25.0) 0 (0.0)
Met withdrawal
criteriab
0 (0.0) 2 (12.5) 3 (21.4)
Investigator
decision
0 (0.0) 0 (0.0) 1 (7.1)
Withdrew
consent
5 (45.5) 2 (12.5) 0 (0.0)
Protocol
deviation
1 (9.1) 0 (0.0) 0 (0.0)
Pharmacokinetic
analysis
populationc
4 (36.4) 8 (50.0) 12 (85.7)
Safety analysis
populationd
10 (90.9) 15 (93.8) 14 (100.0)
a Completed the Week 24 visit.
b Subjects were withdrawn from the study if they met exclusion criteria, received
concomitant medications or were non-compliant with study medication at any time.
Of the 5 subjects who met withdrawal criteria, three subjects were non-compliant,
one relocated, and one became pregnant.
c Received at least three doses of aripiprazole once-monthly and had pharmacokinetic
samples collected through at least 4-weeks after the last dose of aripiprazole once-monthly.
d Received at least one dose of aripiprazole once-monthly.For aripiprazole once-monthly-200, aripiprazole plasma concentrations
were quantiﬁable in 3 subjects at 6 weeks after the last injection and
were in the range 2.45–88.9 ng/mL.
The mean plasma concentrations of dehydro-aripiprazole prior to
the third, fourth, and ﬁfth aripiprazole once-monthly injections were:
aripiprazole once-monthly-200: 19.6, 22.2, and 19.5 ng/mL; aripiprazole
once-monthly-300: 42.8, 57.4, and 53.1 ng/mL; and aripiprazole once-
monthly-400: 46.6, 55.3, and 57.7 ng/mL (Fig. 2b). Dehydro-
aripiprazole plasma concentrations were quantiﬁable in all subjects
with evaluable data at 2 months following the last injection and
were in the range 10.7–58.4 ng/mL and 10.3–77.4 ng/mL for subjects
receiving aripiprazole once-monthly-300 (n = 3) and aripiprazole
once-monthly-400 (n = 6), respectively. For aripiprazole once-
monthly-200, dehydro-aripiprazole plasma concentrationswere quan-
tiﬁable in 3 subjects at 6 weeks after the last injection and were in the
range 1.33–26.8 ng/mL.
After the ﬁfth injection of aripiprazole once-monthly-300 or
aripiprazole once-monthly-400, PK parameters (Css,max, AUCτ, Css,min,
and Css,avg) of aripiprazole and dehydro-aripiprazole increased propor-
tionally to the administered dose (Table 4). When compared with
the 300 mg and 400 mg doses, PK parameters for aripiprazole once-
monthly-200 were not proportional to the administered dose. The
ratio of dehydro-aripiprazole to aripiprazole after the last injection of
aripiprazole once-monthly for mean Css,max and AUCτ PK parameters
ranged from 29.1 to 33.2.3.3. Safety and tolerability
Treatment-emergent AEs (TEAEs) at an incidence of≥5% are sum-
marized in Table 5. Most TEAEs were classiﬁed as mild or moderate in
intensity. Four subjects in the aripiprazole once-monthly-400 group
reported injection-site pain as a common TEAE (no injection site reac-
tion TEAEs were reported in the 200 mg and 300 mg groups). One
subject who reported injection-site pain following the ﬁfth injection
also experienced injection-site discomfort following the ﬁrst once-
monthly injection. All injection site reaction TEAEs were considered
mild in intensity and resolved without sequelae. No AEs pertaining
to suicide or attempted suicide were reported.
Approximately 45% of TEAEs (n = 46/102) were reported during
the co-administration period. The incidence of TEAEs during co-
administration was 40.0% (n = 4/10), 60.0% (n = 9/15) and 57.1%
(n = 8/14) for the aripiprazole once-monthly-200, -300 and -400
groups, respectively.
Four subjects (10.3%) discontinued with treatment due to TEAEs;
three discontinuations occurred in the aripiprazole once-monthly-300
group (one each due to drug dependence, worsening of psychosis and
worsening schizophrenia). Withdrawal due to worsening of psychosis
also occurred in a subject receiving aripiprazole once-monthly-200.
All TEAES leading to discontinuation of study medication occurred dur-
ing the co-administration period.
Mean changes in objective rating movement scales from baseline to
last visit were minimal and not considered to be clinically meaningful.
No change in SAS scores occurred for any aripiprazole once-monthly
doses. No change in AIMS score occurred for patients receiving
aripiprazole once-monthly-200, whereas small changes were observed
in patients receiving aripiprazole once-monthly-300 (0.4, baseline =
0.2) and aripiprazole once-monthly-400 (−0.4, baseline = 0.4). The
baseline BARS score (0.1) and change from baseline to last visit (0.1)
was the same across all three doses.
Mean changes in weight from baseline to last visit were +2.1 kg,
+1.2 kg and +2.2 kg for aripiprazole once-monthly-200, -300 and
-400, respectively. Clinically signiﬁcant weight gain (≥7% from baseline)
was reported in 1/9 (11.1%), 2/14 (14.3%) and 3/12 (25.0%) patients in
the aripiprazole once-monthly-200, -300 and -400 groups, respectively.
Two subjects (one each for aripiprazole once-monthly-300 [7.1%] and
Table 2
Baseline demographic and psychiatric characteristics for the randomized population.
Aripiprazole once-monthly-200
(n = 11)
Aripiprazole once-monthly-300
(n = 16)
Aripiprazole once-monthly-400
(n = 14)
Total
(n = 41)
Baseline demographics
Gender, male n (%) 10 (91.0) 12 (75.0) 7 (50.0) 29 (71.0)
Caucasian 3 (27.0) 6 (38.0) 6 (43.0) 15 (37.0)
Black/African 7 (64.0) 9 (56.0) 6 (43.0) 22 (54.0)
Race, n (%)
American
Asian 0 (0.0) 0 (0.0) 1 (7.0) 1 (2.0)
Other 1 (9.0) 1 (6.0) 1 (7.0) 3 (7.0)
Ethnicity, n (%)
Hispanic/Latino 0 (0.0) 1 (6.0) 1 (7.0) 2 (5.0)
Age, years
Mean (SD) 46.0 (12.7) 43.3 (9.6) 46.8 (9.2) 45.2 (10.3)
Weight, kg
Mean (SD) 84.3 (6.7) 92.8 (17.7) 80.6 (13.3) 86.4 (14.7)
BMI, kg/m2
Mean (SD) 27.3 (2.5) 29.8 (4.4) 28.5 (3.5) 28.7 (3.7)
Baseline disease severity
PANSS total score, mean (SD)a 65.5 (11.7) 64.4 (9.4) 69.4 (8.7) 66.4 (9.9)
CGI-S score, mean (SD) 3.2 (0.6) 3.1 (0.5) 3.3 (0.6) 3.2 (0.6)
SD, standard deviation; BMI, body mass index; PANSS, Positive and Negative Syndrome Scale; CGI-S, Clinical Global Impressions — Severity.
a n = 15 for aripiprazole once-monthly-300 and n = 40 for total.
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from baseline).
No clinically relevant changes frombaselinewere observed for serum
chemistry laboratory tests, hematology results, urinalysis, prolactin
levels, or vital signs. Three subjects (n = 1 [7.1%] in the aripiprazole
once-monthly-300 group and n = 2 [22.2%] in the aripiprazole
once-monthly-200 group) had creatinine phosphokinase (CPK) levels
that met the criteria for potential clinical signiﬁcance (≥3 × upper
limit of normal range [ULN]), none were reported as TEAEs and all of
these patients had elevated CPK levels at baseline. One subject receiving
aripiprazole once-monthly-300 [7.1%] had elevated prolactin values of
potential clinical signiﬁcance (NULN) but this was not reported as a
TEAE.
No worsening of psychotic symptoms was observed during the
study period, as assessed by PANSS total scores and CGI-S scores.
Mean reductions in PANSS total score from baseline to Week 24 (last
observation carried forward [LOCF]) were small (−0.8 to −1.3) with
no signiﬁcant differences across dose groups. Similarly, CGI-S scale scores
for the three treatment groups showed only small changes (−0.2 to 0.1)
from a baseline value of 3.0 to 3.3 (mildly ill) at every visit week during
the study period.
4. Discussion
Monthly administration of 300 and 400 mg of aripiprazole once-
monthly had a PK proﬁle consistent with that of multiple, consecutiveTable 3
Concomitant medications received during treatment with aripiprazole once-monthly (N5.0
Concomitant medication, n (%) Aripiprazole once-monthly-200
(n = 11)
A
(
Total using N1 medication 7 (63.6) 1
Analgesics: paracetamol 1 (9.1)
Anti-Parkinson drugs: benztropine mesilate 2 (18.2)
Anti-inﬂammatory: ibuprofen 2 (18.2)
Diabetes drugs: metformin 0 (0.0)
Lipid-modifying agents: atorvastatin calcium 1 (9.1)
Psychotropics
Lorazepam 2 (18.2)
Quetiapine 0 (0.0)
Risperidone 0 (0.0)
Temazepam 0 (0.0)
Zolpidem tartrate 1 (9.1)daily oral doses of aripiprazole (10–30 mg) (Mallikaarjun et al., 2004).
Mean maximum and trough plasma concentrations after 5 monthly in-
jections of aripiprazole once-monthly-300 and -400 conﬁrmed dosing
simulations. The aripiprazole once-monthly formulation was designed
to provide sustained aripiprazole plasma concentrations over the course
of the dosing interval. As shown here, steady-state plasma concentra-
tions for the 400 mg dose ranged from a mean Cmax of 316 ng/mL to a
mean Cmin of 212 ng/mL. The upper limit of this concentration range
(Cmax) approximates steady-state plasma levels achieved after oral
dosing of 20–30 mg/day, and trough concentrations (Cmin) approximate
steady-state plasma levels achieved after oral dosing of 15–20 mg/day
(Mallikaarjun et al., 2004; Sparshatt et al., 2010). Aripiprazole
once-monthly-200 did not result in mean aripiprazole trough plasma
concentrations comparable to therapeutic concentrations of 10–30 mg
of once-daily oral aripiprazole, suggesting that the 200 mg injectable
dose may be below a meaningful therapeutic threshold. Ratios of
dehydro-aripiprazole to aripiprazole for mean Css,max and AUCτ PK
parameters after the last injection of aripiprazole once-monthly were
29–33%, similar to the 33–39% ratio achieved with a single 15 mg daily
dose of oral aripiprazole in healthy volunteers (Mallikaarjun et al., 2008).
A 2-week oral supplementation regimen was used to ensure a
smooth transition between the oral and extended-release formula-
tions while concentrations of aripiprazole derived from the once-
monthly injection reached therapeutic levels. This 2-week overlap
was based on an exploratory analysis of single-dose aripiprazole
once-monthly and oral steady-state studies. Aripiprazole PK proﬁles% subjects overall).
ripiprazole once-monthly-300
n = 16)
Aripiprazole once-monthly-400
(n = 14)
Total
(n = 41)
3 (81.3) 14 (100) 34 (83.0)
2 (12.5) 3 (21.4) 6 (14.6)
1 (6.3) 3 (21.4) 6 (14.6)
1 (6.3) 3 (21.4) 6 (14.6)
1 (6.3) 2 (14.3) 3 (7.3)
2 (12.5) 0 (0.0) 3 (7.3)
2 (12.5) 2 (14.3) 6 (14.6)
1 (6.3) 3 (21.4) 4 (9.8)
2 (12.5) 1 (7.1) 3 (7.3)
3 (18.8) 1 (7.1) 4 (9.8)
3 (18.8) 5 (35.7) 9 (22.0)
Fig. 2. Mean plasma concentrations for (a) aripiprazole and (b) dehydro-aripiprazole following ﬁve injections of aripiprazole once-monthly-200, -300 and -400, beginning with
baseline levels at Day 1 prior to the ﬁrst injection (following stabilization with oral aripiprazole for ≥14 days). Injections were administered on Day 1 and at the beginning of
Weeks 5, 9, 13 and 17 (indicated by arrows on the graphs). The end-of-treatment visit was Week 24; the ﬁnal PK sample was taken at Week 25 (end of week 24). aThe x-axis
shows the time at the end of each week following the ﬁrst injection of aripiprazole once-monthly. Accordingly, the value at Week 24 corresponds to the PK assessment taken at
the beginning of Week 25 and monthly injections are shown at baseline and Weeks 4, 8, 12 and 16, corresponding to study visits at the beginning of Weeks 1, 5, 9, 13 and 17,
respectively.
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concentrations were reached within 5–7 days, supporting this switching
strategy. In our study, patients received oral supplementation with
10 mg oral aripiprazole. However, the recently approved label for
once-monthly aripiprazole is based on oral supplementation with oral
aripiprazole at 10 mg to 20 mg for 14 days, as well as allowing patients
to continue with their existing oral atypical antipsychotic during the
overlap period (Otsuka Pharmaceutical Co., Ltd., 2013). Additionally, a
separate study has shown that switching patients to aripiprazoleonce-monthly from oral atypical antipsychotics other than oral
aripiprazole was well tolerated, with an AE proﬁle consistent with re-
ports of aripiprazole once-monthly concomitant with oral aripiprazole
(Potkin et al., 8–11 November 2012).
Psychopathological symptoms remained stable during the study
period and the majority of TEAEs reported were mild or moderate.
Similar to other currently available long-acting antipsychotic formu-
lations (Chue et al., 2005; Hough et al., 2010; Kane et al., 2010), the
safety and tolerability of the aripiprazole once-monthly formulation
Table 4
Pharmacokinetic parameters of aripiprazole and dehydro-aripiprazole after ﬁve injections of aripiprazole once-monthly by treatment dose.
PK parameter Aripiprazole once-monthly-200
(n = 4)
Aripiprazole once-monthly-300
(n = 8)
Aripiprazole once-monthly-400
(n = 10)
Aripiprazole
Css,max, ng/mL, mean (SD) 100 (68.4) 269 (128) 316 (160)
tmax, day, median (range) 5.0 (4.0–27.9) 6.5 (0.5–21.2) 7.1 (3.0–11.2)
AUCτ, μg·h/mL, mean (SD) 54.5 (39.4) 140 (58.4) 163 (88.8)
t1/2,z, day, mean (SD) ND 29.9 (8.0)a 46.5 (10.8)b
Css,min, ng/mL, mean (SD)c 95.0 (86.2) 156 (67.7) 212 (113)
Dehydro-aripiprazole
Css,max, ng/mL, mean (SD) 30.3 (19.8) 74.7 (20.8) 89.4 (37.9)
tmax, day, median (range) 5.5 (0.0–27.9) 12.5 (0.5–22.2) 6.6 (3.0–14.0)
AUCτ, μg·h/mL, mean (SD) 14.7 (9.5) 38.9 (13.2) 47.8 (19.1)
Css,min, ng/mL, mean (SD)c 26.2 (24.7) 54.1 (21.1) 64.1 (27.0)
PK, pharmacokinetic; SD, standard deviation; AUC, area under the curve; ND, not determined.
a n = 4.
b n = 6.
c Css,min = concentration 28 days post-injection.
287S. Mallikaarjun et al. / Schizophrenia Research 150 (2013) 281–288are comparable to those of the oral formulation (Marder et al., 2003).
However, these comparisons of aripiprazole are between individual
reports as direct comparative studies are not available.
All three doses of aripiprazole once-monthly demonstrated accept-
able safety and tolerability. Of note was a higher discontinuation rate
with aripiprazole once-monthly-200 compared with aripiprazole once-
monthly-300 and -400. It could be speculated that the higher discontin-
uation rate in patients receiving aripiprazole once-monthly-200 may
have been a result of sub-therapeutic plasma concentrations. Although
these patients did not show a higher proportion of worsening of psycho-
sis symptoms, the open-label study design and the limited number of
subjects who completed aripiprazole once-monthly-200 limit interpre-
tation of the potential correlation between efﬁcacy and PK results.
The majority of TEAEs were reported as mild or moderate. The most
common TEAEs (overall incidence) were vomiting, injection-site pain,
upper respiratory tract infection and tremor, all of which occurred in
10.3% of the total population. Injection-site pain was only reported in
aripiprazole once-monthly-400 patients despite equivalent absolute in-
jection volumes suggesting that administration of the injectable formula-
tion was generally well tolerated. A total of 17.1% of subjects showed
weight gain of≥7% from baseline, with the highest incidence in patients
receiving aripiprazole once-monthly-400 (25.0%). These values, al-
though higher than previously reported in a larger randomizedTable 5
Summary of adverse events with an incidence N5% of all randomized subjects (n = 39).
Adverse event, n (%) Aripiprazole once-monthly-200
(n = 10)
Aripiprazole
(n = 15)
Injection-site pain 0 (0.0) 0 (0.0)
Tremor 0 (0.0) 1 (6.7)
URTI 1 (10.0) 1 (6.7)
Vomiting 0 (0.0) 2 (13.3)
Nasopharyngitis 0 (0.0) 1 (6.7)
Muscle strain 0 (0.0) 0 (0.0)
Musculoskeletal stiffness 0 (0.0) 0 (0.0)
Sedation 0 (0.0) 0 (0.0)
Rash 0 (0.0) 0 (0.0)
Headache 2 (20.0) 0 (0.0)
Akathisia 1 (10.0) 1 (6.7)
Insomnia 1 (10.0) 1 (6.7)
Cough 1 (10.0) 0 (0.0)
Back pain 0 (0.0) 1 (6.7)
Anxiety 0 (0.0) 1 (6.7)
Hallucination, auditory 0 (0.0) 1 (6.7)
Fatigue 1 (10.0) 1 (6.7)
ECG QTc interval prolonged 1 (10.0) 2 (13.3)
Somnolence 1 (10.0) 2 (13.3)
Psychotic disorder 1 (10.0) 1 (6.7)
Nausea 0 (0.0) 2 (13.3)
URTI, upper respiratory tract infection; ECG, electrocardiogram.controlled trial (Kane et al., 2012), could be inﬂated due to the relatively
small sample size. No new safety concerns were raised regarding labora-
tory parameters, vital signs, electrocardiograms or EPS ﬁndings. The inci-
dence of potentially clinically relevant CPK elevation all occurred in
patients with elevated levels at baseline. No laboratory values of
potential clinical signiﬁcance were identiﬁed for patients receiving
aripiprazole once-monthly-400.
Collectively, the PK proﬁle and the clinical data suggest that
aripiprazole once-monthly at doses of 300 and 400 mg appear to be
most suitable for further investigation in the treatment of schizophre-
nia. These ﬁndings are supported by recently published clinical data
showing the efﬁcacy of aripiprazole once-monthly-300 and -400 mg
in patients with schizophrenia (Fleischhacker et al., 2–6 December
2012; Kane et al., 2012).
5. Limitations
A limitation of our study is the low numbers of subjects included
in each dose category; however, the study was designed to be explor-
atory with ﬁndings intended to provide guidance for design of future
studies. Our ﬁndings were speciﬁc to a population that was not per-
mitted inhibitors and inducers of CYP3A4 and inhibitors of CYP2D6.
However, aripiprazole once-monthly can be administered to patientsonce-monthly-300 Aripiprazole once-monthly-400
(n = 14)
Total (n = 39)
4 (28.6) 4 (10.3)
3 (21.4) 4 (10.3)
2 (14.3) 4 (10.3)
2 (14.3) 4 (10.3)
2 (14.3) 3 (7.7)
2 (14.3) 2 (5.1)
2 (14.3) 2 (5.1)
2 (14.3) 2 (5.1)
2 (14.3) 2 (5.1)
1 (7.1) 3 (7.7)
1 (7.1) 3 (7.7)
1 (7.1) 3 (7.7)
1 (7.1) 2 (5.1)
1 (7.1) 2 (5.1)
1 (7.1) 2 (5.1)
1 (7.1) 2 (5.1)
0 (0.0) 2 (5.1)
0 (0.0) 3 (7.7)
0 (0.0) 3 (7.7)
0 (0.0) 2 (5.1)
0 (0.0) 2 (5.1)
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Pharmaceutical Co., Ltd., 2013). Seven patients received concomi-
tant medication with either risperidone or quetiapine during the
study. These medications were largely administered for treatment
of psychosis/schizophrenia during theperiod of extendedPKassessments
at a point when the next injection of aripiprazole once-monthly would
have been due. Despite these limitations, the consistency inmean plasma
concentration levels across multiple doses of aripiprazole once-monthly
implies that the PK ﬁndings reﬂect the sustained concentrations of
aripiprazole provided by the once-monthly dosing regimen.
6. Conclusions
Injections of aripiprazole at doses of 300 and 400 mg provided
sustained concentrations of aripiprazole supporting a once-monthly
dosing schedule, with a PK proﬁle comparable to that of multiple,
consecutive daily doses of oral aripiprazole (10–30 mg). Aripiprazole
once-monthly appears to be a new option for the long-term manage-
ment of schizophrenia.
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